Allakos Shares Double on AK002 Phase 2 Results and Earnings
Source: Streetwise Reports  (8/5/19)
Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. More >

Gaia Grow Corp. Plants 1,494 Acres of Hemp in Canada and Plans First Harvest in 2 Months
Source: Peter Epstein for Streetwise Reports  (8/1/19)
Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange. More >

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%
Source: Streetwise Reports  (8/1/19)
Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. More >

EMA Opinion Bodes Well for Biopharma's Drug Getting Orphan Status
Source: Streetwise Reports  (7/31/19)
The designation, opinion and asset are discussed in a ROTH Capital Partners report. More >

Mylan Gets a Shot in the Arm with Pfizer Merger Deal
Source: Streetwise Reports  (7/29/19)
EpiPen manufacturer Mylan N.V. announced that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. More >

Anixa Licenses Another Potential Blockbuster
Source: Daniel Carlson for Streetwise Reports  (7/24/19)
Daniel Carlson of Tailwinds Research discusses a major collaboration with the Cleveland Clinic for his top pick stock of the year. More >

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report
Source: Streetwise Reports  (7/24/19)
Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. More >

Biotech Firm ''Creating Innovative Solutions' for Female Health
Source: Streetwise Reports  (7/23/19)
The company's most advanced assets are discussed in a Dawson James Securities report. More >

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'
Source: Streetwise Reports  (7/23/19)
The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. More >

Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'
Source: Streetwise Reports  (7/23/19)
The specifics and benefits of the deal are discussed in an H.C. Wainwright & Co. report. More >

Biopharma Presents Data on Its Therapeutic Candidates at Alzheimer's Conference
Source: Streetwise Reports  (7/22/19)
The company discussed both its Alzheimer's disease and ALS programs. More >

Biopharma Licenses Sustained Release Technology to Gilead for HIV Product
Source: Streetwise Reports  (7/22/19)
The two California-based companies will collaborate on specific related development activities. More >

Biopharma Receives PDUFA Goal Date for Nonopioid Pain Drug
Source: Streetwise Reports  (7/18/19)
The FDA deemed the firm's submission for analgesic approval complete. More >

Top Pick Status Given to Small-Cap with Pain Drug Candidate
Source: Streetwise Reports  (7/17/19)
The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. More >

Seattle Genetics Shares Head Higher After Positive Earnings and ADCETRIS Sales Expansion
Source: Streetwise Reports  (7/17/19)
Seattle Genetics announced a 28.3% increase in net sales for its second quarter 2019 powered by ADCETRIS sales along with a promising pipeline. More >

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued
Source: Streetwise Reports  (7/16/19)
A description of the asset and its potential are provided in a Dawson James report. More >

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead
Source: Streetwise Reports  (7/15/19)
Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company. More >

Illumina Shares Fall Sharply on Lower Revenue Guidance
Source: Streetwise Reports  (7/12/19)
Illumina Inc. shares traded down more than 15% as the company reported lower preliminary Q2/19 revenues and updated its annual revenue guidance. More >

CVS Declares Quarterly Dividend and Gets a Boost from Relaxed Rebate Policy
Source: Streetwise Reports  (7/11/19)
CVS Healthcare announced a $0.50/share quarterly dividend yesterday and got an added boost today as news spreads regarding easing of federal restrictions on pharmacy rebate plans. More >

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication
Source: Streetwise Reports  (7/10/19)
A study description and expected data readouts this year are provided in a ROTH Capital Partners report. More >

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'
Source: Streetwise Reports  (7/10/19)
The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. More >

Sangamo and Pfizer Report Positive Results for Hemophilia A Study
Source: Streetwise Reports  (7/8/19)
Sangamo Therapeutics and partner Pfizer reported positive results for phase 1/2 Alta study for hemophilia A at the International Society on Thrombosis and Hemostasis Congress in Melbourne, Australia. More >

Coverage Initiated on Biopharma With 'Low Risk/High Margin Assets'
Source: Streetwise Reports  (7/3/19)
The case is made in a ROTH Capital Partners report for investing in this U.S.-based pharma having multiple shots on goal. More >

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress
Source: Streetwise Reports  (7/2/19)
Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. More >

Bioasis Engages With the FDA: Here's What It Means
Source: Daniel Carlson for Streetwise Reports  (7/2/19)
Daniel Carlson of Tailwinds Research examines the implications of correspondence with the regulatory agency as the company advances its lead candidate addressing brain cancer. More >